Abstract
The goal of the paper is to study characteristics of dyspeptic syndrome in hemodialysis patients receiving renal replacement therapy. Materials and Methods. During an open clinical trial, we formed a group of hemodialysis patients (n=50) with end-stage chronic kidney disease (CKD C5). All patients were assessed for the clinical manifestations, dyspeptic syndrome severity, and laboratory data. All patients underwent esophagogastroduodenoscopy (EGDS). Results. All 50 (100 %) patients included in the study had dyspeptic syndromes. The most common symptoms were nausea (46 %), belching (44 %), and heartburn (38 %). At the same time, 56 % of patients had high dyspepsia index. When analyzing the correlation between dyspepsia index and dialysis therapy,a direct connection was established (ρ=0.281, p=0.048). It was revealed that the dialysis therapy duration impacted the dyspepsia index. The most common pathology of the upper gastrointestinal tract was chronic gastritis, diagnosed in 84 % of patients. Chronic duodenitis was found in 50 % of patients, and gastroduodenal ulcer was observed in 6 % of patients. Conclusion. Hemodialysis patients receiving renal replacement therapy are at risk for dyspeptic syndrome accompanying upper gastrointestinal tract organic pathology. Early detection of dyspeptic syndrome in hemodialysis patients is of great importance for the timely diagnostic and corrective therapeutic measures.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.